Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Pipeline Review, H2 2016', provides in depth analysis on Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted pipeline therapeutics. 

The report provides comprehensive information on the Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) 
- The report reviews Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) Overview 7
Therapeutics Development 8
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Products under Development by Stage of Development 8
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Products under Development by Therapy Area 9
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Products under Development by Indication 10
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Products under Development by Companies 13
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 18
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Companies Involved in Therapeutics Development 19
Allergan Plc 19
Brickell Biotech, Inc. 20
Ligand Pharmaceuticals, Inc. 21
Merck & Co., Inc. 22
Novartis AG 23
Oxagen Limited 24
Panmira Pharmaceuticals, LLC. 25
Pulmagen Therapeutics LLP 26
Taisho Pharmaceutical Holdings Co., Ltd. 27
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Drug Profiles 28
ADC-3680 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
ADC-7405 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
ADC-9971 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
AM-211 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
AM-461 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
BBI-5000 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
fevipiprant - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
MK-1029 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
OC-2417 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
setipiprant - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
TASP-0376377 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Timapiprant - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Dormant Projects 46
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Discontinued Products 49
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Featured News & Press Releases 50
Sep 28, 2016: Eleventa Announce Completion of Patient Enrollment in Phase 3 Clinical Trial of CRTH2 Antagonist Timapiprant for the Treatment of Allergic Asthma 50
Aug 05, 2016: Asthma pill could reduce symptoms in severe sufferers 50
Sep 22, 2015: KYTHERA Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss 52
Jun 16, 2015: Atopix Therapeutics Secures Funding to Broaden Development of CRTH2 Antagonists for TH2-Mediated Disease 53
Aug 01, 2014: Pulmagen's lead CRTh2 antagonist, ADC3680, completes patient recruitment in Phase II study 53
Mar 03, 2014: Atopix Therapeutics Announces Positive Phase IIb Results for Once Daily OC459 in Asthma 54
Nov 19, 2013: Atopix Therapeutics Recruits First Patient in Phase 2 Trial of OC459 for Atopic Dermatitis 54
May 29, 2013: Atopix Therapeutics Receives Biomedical Catalyst Grant To Pursue Development Of OC459 In Treatment Of Atopic Dermatitis 55
Jul 15, 2011: Oxagen Announces Publication Of Phase IIa Asthma Trial Data For OC000459 Which Shows Promise As New Oral Treatment For Asthma And Related Disorders 56
May 23, 2011: Actelion's CRTH2 Antagonist Meets primary Endpoint in Phase II Study in Patients with Seasonal Allergic Rhinitis 56
May 26, 2010: Amira Announces Second DP2 Antagonist Patent Grant In UK 57
Dec 09, 2009: Oxagen Announces Completion Of Recruitment In Phase IIb Dose Range-Finding Clinical Trial In New Oral Treatment For Asthma 57
Dec 09, 2009: Oxagen Completes Recruitment Of Patients For Phase IIb Clinical Trial Of OC000459 For Asthma 58
Dec 03, 2009: Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data Of AM461 58
Dec 03, 2009: Amira Pharmaceuticals Announces Phase 1 Clinical Results Of AM461, For The Novel Treatment Of Asthma, Chronic Obstructive Pulmonary Disease (COPD) And Allergic Rhinitis. 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 17
Number of Products by Stage and Molecule Type, H2 2016 18
Pipeline by Allergan Plc, H2 2016 19
Pipeline by Brickell Biotech, Inc., H2 2016 20
Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 21
Pipeline by Merck & Co., Inc., H2 2016 22
Pipeline by Novartis AG, H2 2016 23
Pipeline by Oxagen Limited, H2 2016 24
Pipeline by Panmira Pharmaceuticals, LLC., H2 2016 25
Pipeline by Pulmagen Therapeutics LLP, H2 2016 26
Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016 27
Dormant Projects, H2 2016 46
Dormant Projects (Contd..1), H2 2016 47
Dormant Projects (Contd..2), H2 2016 48
Discontinued Products, H2 2016 49